Search - tctmd.com

Displaying 61 - 71 of 71

Sort: Relevancy | Date

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

September 14, 2017

Dabigatran Reversal Agent Yields No Surprises in Final RE-VERSE AD Study Results

News Daily News

Dabigatran Reversal Agent Yields No Surprises in Final RE-VERSE AD Study Results

July 14, 2017

Study Suggests VKA Monotherapy Sufficient in Patients With A-fib but No CAD

News Daily News

Study Suggests VKA Monotherapy Sufficient in Patients With A-fib but No CAD

Yael L. Maxwell

June 20, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

News Daily News

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

May 17, 2017

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

News Daily News

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

March 03, 2017

News Daily News

Patients With A-fib Still Have High Mortality Risk After Appropriate Anticoagulation Is Started

December 05, 2016

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

August 27, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.